公开(公告)号：EP2307058B1

公开(公告)日：2017-09-13

申请号：EP09769797.3

申请日：2009-06-24

申请人： Enzymotec Ltd.

发明人： BEN-DROR, Gai ,  PLATT, Dorit ,  FARKASH, Orly ,  ZUABI, Rassan ,  BAR-ON, Zohar ,  SHULMAN, Avidor ,  PELLED, Dori ,  RICHTER, Yael

IPC分类号： A61K47/50 ,  A61P25/28 ,  C07F9/10 ,  A23D7/01 ,  A23D9/013 ,  A21D2/32 ,  A61K31/66 ,  A61K31/685 ,  A23L33/12

CPC分类号： A61K47/544 ,  A21D2/32 ,  A23D7/013 ,  A23D9/013 ,  A23L33/12 ,  A23L33/30 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/201 ,  A61K31/202 ,  A61K31/66 ,  A61K31/685 ,  C07F9/10 ,  A23V2200/322 ,  A23V2250/1882 ,  A23V2250/1942 ,  A23V2250/1842

摘要： This invention provides a preparation comprising serine glycerophospholipids which comprise a mixture of serine glycerophospholipids comprising eicosapentaenoic acid (EPA) and serine glycerophospholipids comprising docosahexaenoic acid (DHA), wherein each such serine glycerophospholipid comprising EPA and each such serine glycerophospholipid comprising DHA has the formula (I): wherein R″ is serine; wherein one of R or R′ is acyl EPA or acyl DHA and the other of R or R′ is hydrogen or an acyl group; wherein the combined amount of EPA and DHA present in such mixture of serine glycerophospholipids constitutes 10-50% by weight of the total fatty acids content of the serine glycerophospholipids in said preparation; and wherein the mixture is not identical to naturally occurring human or mammalian brain PS.

摘要翻译： 本文所述的本发明提供了一种制剂，其包含具有特定含量和LA，亚麻酸（α-亚麻酸，γ-亚麻酸）DHA和EPA的特定偶联模式的非哺乳动物来源的丝氨酸甘油磷脂缀合物的混合物，其依赖于利用不同的 脂质来源以及这些制剂的用途。

公开(公告)号：EP2563167B1

公开(公告)日：2015-02-25

申请号：EP11721378.5

申请日：2011-04-26

申请人： Enzymotec Ltd.

发明人： BAR-YOSEPH, Fabiana ,  MANOR, Yonatan ,  COHEN, Tzafra ,  GOREN, Amit ,  LIFSHITZ, Yael

IPC分类号： A23L1/29 ,  A23L1/30 ,  A61K31/23

CPC分类号： A61K31/23 ,  A23L33/115 ,  A23L33/125 ,  A23L33/15 ,  A23L33/16 ,  A23L33/17 ,  A23L33/40 ,  A23V2002/00

公开(公告)号：EP1663157B1

公开(公告)日：2012-11-28

申请号：EP04770566.0

申请日：2004-09-26

申请人： Enzymotec Ltd.

发明人： PLATT, Dorit ,  SHULMAN, Avidor ,  BEN DROR, Gai ,  SCHEINMAN, Neta ,  TWITO, Yoni ,  ZUABI, Rassan

IPC分类号： C12P13/06 ,  C12P9/00 ,  C07F9/10 ,  A61K31/685 ,  A23J7/00

CPC分类号： C12P13/06 ,  A23J7/00 ,  A23L33/10 ,  A23V2002/00 ,  A61K31/685 ,  A61K45/06 ,  C07F9/103 ,  C07F9/106 ,  C12P9/00 ,  A23V2250/1852 ,  A23V2200/322

公开(公告)号：EP1898722A2

公开(公告)日：2008-03-19

申请号：EP06728307.7

申请日：2006-04-27

申请人： Enzymotec Ltd.

发明人： SHULMAN, Avidor ,  ZUABI, Rassan ,  BEN DROR, Gai ,  TWITO, Yoni ,  PELLED, Dori ,  HERZOG, Yael

IPC分类号： A23L1/29 ,  A23J7/00 ,  A61P25/28 ,  C07F9/10

CPC分类号： A23J7/00 ,  A23L33/115 ,  A23V2002/00 ,  A23V2250/185 ,  A23V2250/1852 ,  A23V2250/1848

摘要： Disclosed herein are polar lipid mixtures, comprising glycerophospholipids such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS) and phosphatidylinositol (PI), and sphingolipids such as sphyngomyelin (SM). Most importantly, the ratio of phospholipids in said mixture is comparable to that of HMF, and is represented by SM>PC>PE>PS>PI or SM=PC>PE>PS>PI. Processes for the preparation of said mixtures and uses thereof are also described herein.

公开(公告)号：EP1796726A2

公开(公告)日：2007-06-20

申请号：EP05764602.8

申请日：2005-08-10

申请人： Enzymotec Ltd.

发明人： SHULMAN, Avidor ,  PELLED, Dori ,  COHEN, Tzafra ,  FARKASH, Orly

IPC分类号： A61K45/06

CPC分类号： A23D9/013 ,  A23L33/11 ,  A23L33/12 ,  A23V2002/00 ,  A61K31/20 ,  A61K31/23 ,  A61K31/56 ,  A61K31/575 ,  A61K2300/00 ,  A23V2200/332 ,  A23V2200/3262 ,  A23V2250/182 ,  A23V2250/2136

摘要： Methods of treatment of conditions which require phytosterol therapy without adversely affecting the bioavailability of lipophilic vitamins or lipophilic drugs, consisting of administering a mixture of phytosterol ester(s) (PS-E) and 1,3-diglyceride(s) (DAG) dissolved in an edible oil or fat are described herein, together with a method of improving weight management and a method of treating metabolic conditions that result in overweight. Dietary nutrients and food supplements containing said mixture are also described herein.

公开(公告)号：EP3457862A1

公开(公告)日：2019-03-27

申请号：EP16759879.6

申请日：2016-08-17

申请人： Enzymotec Ltd.

发明人： WIDBERG, Asher ,  BEN-DROR, Gai ,  ILITZKY GUR, Maria ,  HERZOG, Yael

IPC分类号： A23D9/04 ,  A23L33/115 ,  A23L33/00 ,  A61K8/92

公开(公告)号：EP3220753A2

公开(公告)日：2017-09-27

申请号：EP15831064.9

申请日：2015-11-19

申请人： Enzymotec Ltd.

发明人： ZAAROOR REGEV, Daphna ,  CHUDNOW, Robert ,  RICHTER, Yael ,  SORIA ARTZI, Gali, Olga

IPC分类号： A23L33/115 ,  A23L33/12 ,  A61K31/201 ,  A61K31/202 ,  A61K31/685 ,  A61P25/00

CPC分类号： A61K31/685 ,  A23L33/115 ,  A23L33/12 ,  A23V2002/00 ,  A61K31/661 ,  A61K2300/00

摘要： The preparation of the present invention was found to be effective for the majority of patients diagnosed with autism. In patients characterized by delayed language development and non-expressive/non-emotional communication patterns, the preparation of the invention was found to be more effective than in patients that were diagnosed with autism without delayed language development and with expressive/emotional communication patterns, even though all patients consumed the preparation for a similar duration. Specific analysis for the type and quality of the improvement detected within the group of patients characterized by delayed language development and non-expressive/non-emotional communication patterns revealed that the majority of patients improved in various communication abilities: speech, language, conversation, and social play.

摘要翻译： 发现本发明的制剂对于诊断患有自闭症的大多数患者是有效的。 在患有迟发语言发展和非表达/非情感交流模式的患者中，发现本发明的制备比被诊断为患有孤独症但没有语言发育迟缓并具有表达/情感交流模式的患者更有效，甚至 尽管所有患者都需要准备相似的时间。 在语言发展迟缓和非表达/非情感交流模式的患者群体中检测到的改善类型和质量的具体分析显示，大多数患者的各种交流能力得到改善：言语，语言，谈话和 社交游戏。

公开(公告)号：EP3203853A1

公开(公告)日：2017-08-16

申请号：EP15805252.2

申请日：2015-10-08

申请人： Enzymotec Ltd.

发明人： BEN-DROR, Gai ,  NUMA, Ran ,  SHEFFER DEE-NOOR, Shani

IPC分类号： A23D9/013 ,  C11B1/10 ,  C11B3/00 ,  C11B5/00 ,  A23L33/105 ,  A23L33/115 ,  A23L33/12 ,  A23L17/00 ,  A23L29/10

CPC分类号： A61K35/612 ,  A23D9/007 ,  A23D9/013 ,  A23J7/00 ,  A23L17/00 ,  A23L29/10 ,  A23L33/10 ,  A23L33/105 ,  A23L33/115 ,  A23L33/12 ,  A23L33/175 ,  A23L33/30 ,  A23V2002/00 ,  C11B1/10 ,  C11B5/0028 ,  C11B5/0035

摘要： The present invention provides marine lecithin preparations including a marine lecithin and one or more exogenous antioxidants. Also provided are a nutritional, pharmaceutical, or nutraceutical composition or a functional or medical food including the marine lecithin preparations. Also provided are processes for making the marine lecithin preparations. Also provided are methods of treating or preventing a disease or disorder, the methods including administering to a subject a therapeutically effective amount of the marine lecithin preparations. Also provided are methods of decreasing an oxidation status of a composition administrated to a subject in need of marine lecithin, the methods including administration of the composition and co-administration of an effective amount of the marine lecithin preparations to the subject in need of marine lecithin.

摘要翻译： 本发明提供海洋卵磷脂制剂，其包含海洋卵磷脂和一种或多种外源性抗氧化剂。 还提供营养，药物或营养食品组合物或功能或医疗食品，包括海洋卵磷脂制剂。 还提供了制备海洋卵磷脂制剂的方法。 还提供治疗或预防疾病或病症的方法，所述方法包括向受试者施用治疗有效量的海洋卵磷脂制剂。 还提供了降低施用于需要海洋卵磷脂的受试者的组合物的氧化状态的方法，所述方法包括施用组合物和将有效量的海洋卵磷脂制剂联合施用至需要海洋卵磷脂的受试者 。

公开(公告)号：EP3171706A1

公开(公告)日：2017-05-31

申请号：EP15781413.8

申请日：2015-07-23

申请人： Enzymotec Ltd.

发明人： WIDBERG, Asher ,  HERZOG, Yael

IPC分类号： A23J7/00 ,  C07F9/10

CPC分类号： A61K31/685 ,  A23G3/40 ,  A23J7/00 ,  A23L33/00 ,  A23L33/10 ,  A23L33/40 ,  A23V2002/00 ,  A61K9/1611 ,  C07F9/103

摘要： Phosphatidylserine powder compositions of the present invention were found to provide more homogeneous dispersion and demonstrate reduced sedimentation, compared to conventional phosphatidylserine powders, when mixed without processing by high pressure homogenization in water or other liquids. The composition of the present invention comprises phosphatidylserine and at least 80% (w/w) of the composition has a particle size of 500 microns or less. Nutritional, nutraceutical, or pharmaceutical compositions including the phosphatidylserine powder compositions of the present invention are also provided. Process for preparing phosphatidylserine powder compositions according to the present invention is also provided and includes sieving.

摘要翻译： 发现本发明的磷脂酰丝氨酸粉末组合物提供了更均匀的分散，并且与常规磷脂酰丝氨酸粉末相比，当与水或其他液体中的高压均质混合而未经处理混合时，沉降减少。 本发明的组合物包含磷脂酰丝氨酸，并且组合物的至少80％（w / w）具有500微米或更小的粒度。 还提供了包括本发明的磷脂酰丝氨酸粉末组合物的营养，营养药物或药物组合物。 还提供了根据本发明制备磷脂酰丝氨酸粉末组合物的方法，其包括筛分。

公开(公告)号：EP2207429B2

公开(公告)日：2016-12-28

申请号：EP08808110.4

申请日：2008-10-02

申请人： Enzymotec Ltd.

发明人： BAR YOSEF, Fabiana ,  BEN DROR, Gai ,  COHEN, Tzafra ,  LIFSHITZ, Yael

IPC分类号： A23D9/00 ,  C11C3/08 ,  A61K31/23

CPC分类号： A61K31/231 ,  A21D2/165 ,  A23D7/001 ,  A23D7/003 ,  A23K20/158 ,  A23K50/10 ,  A23K50/40 ,  A23L33/115 ,  A23L33/12 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/23 ,  A61K31/232